Malignant lymphoma: pathophysiology and current therapy

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Advances in understanding lymphoma molecular pathogenesis.
• Integration of molecular markers into disease classification and diagnosis.

Purpose of the Study:

• Review key topics in lymphoma molecular pathogenesis.
• Discuss implications for targeted therapy and clinical trial design.
• Explore mechanisms of immune checkpoint inhibitors in lymphoma.

Main Methods:

• Literature review of recent advances in lymphoma research.
• Analysis of WHO classification updates and diagnostic recommendations.
• Evaluation of targeted therapy efficacy based on molecular subtypes.
• Discussion of immune checkpoint inhibitor mechanisms.

Main Results:

• Incorporation of disease-specific mutations (e.g., MYD88 L265P, BRAF V600E) into diagnostics.
• Recommendation for cell-of-origin determination in diffuse large B-cell lymphoma (DLBCL).
• Demonstrated differential efficacy of ibrutinib/lenalidomide in ABC-type DLBCL.
• Discussion of anti-programmed cell death 1 antibody efficacy in Hodgkin lymphoma.

Conclusions:

• Molecular pathogenesis is crucial for defining lymphoma entities and guiding novel therapies.
• Targeted therapies and immune checkpoint inhibitors show promise in specific lymphoma subtypes.
• Personalized treatment strategies based on molecular profiling are advancing lymphoma care.